A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)
Associated ConditionsLung Cancer
This study is for an investigational study drug called poziotinib for the treatment for EGFR or HER2 Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer. Poziotinib is a new type of treatment and is considered investigational. Investigational means that it has not yet been approved by the U.S. Food and Drug Administration (FDA) because we do not know enough about the benefits or side effects of poziotinib in the treatment for EGFR or HER2 Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer.
This study is currently enrolling.